Literature DB >> 7683687

Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain.

J Wu1, E Amandoron, X Li, M A Wainberg, M A Parniak.   

Abstract

A series of monoclonal antibodies against p51/p66 human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT) were prepared by immunizing mice with the native enzyme immobilized on nitrocellulose. One of these antibodies, designated 1E8, was found to inhibit both RNA-dependent and DNA-dependent polymerase activities of RT but had no effect on the RNase H activity of the enzyme. This inhibition was noncompetitive with respect to primer/template and competitive with respect to deoxynucleoside triphosphate (dNTP). The extent of 1E8 inhibition of RT polymerase activity decreased with increasing concentrations of dNTP in the incubation but was not affected by changes in primer/template concentration. 1E8 bound equally well in solution to both free RT and to the RT-primer/template complex. However, binding to the latter was significantly reduced by the addition of increasing concentrations of dNTP. The ability of dNTP to inhibit the interaction of 1E8 with the RT-primer/template complex was dependent on the identity of the homopolymeric primer/template used; only that dNTP complementary to the template was effective in this respect. 1E8 bound to the p51/p66 reverse transcriptase heterodimer in solution and reacted with both p51 and p66 subunits of reverse transcriptase on Western blots. The antibody is therefore presumed to recognize a linear surface epitope on the enzyme. 1E8 was found to specifically recognize a peptide with the sequence KKDSTKWRK. This sequence corresponds to residues 65-73 of HIV-1 reverse transcriptase, a region identified as highly antigenic by several computer algorithms. Two mutations within this sequence have been identified with resistance to 3'-azido,3'-deoxythymidine. We conclude that residues 65-73 of HIV-1 reverse transcriptase may be at or near the polymerase active site of the enzyme, and may form part of the deoxynucleoside triphosphate binding domain of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683687

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

2.  3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.

Authors:  E J Arts; M E Quiñones-Mateu; J L Albright; J P Marois; C Hough; Z Gu; M A Wainberg
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.

Authors:  J M Cherrington; A S Mulato; M D Fuller; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Human recombinant antibody fragments neutralizing human immunodeficiency virus type 1 reverse transcriptase provide an experimental basis for the structural classification of the DNA polymerase family.

Authors:  N Gargano; S Biocca; A Bradbury; A Cattaneo
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1.

Authors:  Y Huang; A Khorchid; J Wang; M A Parniak; J L Darlix; M A Wainberg; L Kleiman
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis.

Authors:  A M Martín-Hernández; E Domingo; L Menéndez-Arias
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

7.  Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.

Authors:  Z Gu; X Li; Y Quan; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site.

Authors:  Michael E Abram; Stefan G Sarafianos; Michael A Parniak
Journal:  Retrovirology       Date:  2010-02-01       Impact factor: 4.602

9.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

Authors:  Z Gu; Q Gao; H Fang; H Salomon; M A Parniak; E Goldberg; J Cameron; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs.

Authors:  Z Gu; E J Arts; M A Parniak; M A Wainberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.